According to Beisel, this opens up future research opportunities: “There is a whole class of systems, called type III systems, that recognize RNA but rely on other proteins for collateral RNA or DNA cleavage. The findings of the research team provide a better understanding of the nuclease, laying the groundwork for new innovative therapeutics.Īs a next step, the researchers plan to investigate how this threshold extends to other CRISPR-Cas systems that recognize RNA. “This provides an extra factor to consider when applying Cas13 to gene silencing,” Beisel adds. Our work indicates that RNA levels could help explain this difference,” Vialetto notes. “It has always been a curiosity that Cas13 induces dormancy in bacteria through widespread RNA cleavage, yet only cleaves the target RNA in human cells. The nuclease Cas13 has the potential to be used in the future to fight viral diseases or to silence adverse genes. New possibilities for therapies and gene silencing Certain invaders, for example, contain antibiotic resistance genes and only integrate into the bacterial genome without killing the cell.
According to Beisel, this is important because some infections can actually be beneficial to a bacterium.
“Cells can therefore decide if an infection poses a threat,” Vialetto summarizes. This additional “decision aid” allows the cells to differentiate between an acute and potentially lethal infection and a benign infection that can be ignored. “The fact that the concentration of the target RNA also plays an important role was completely unexpected,” she elaborates. “Up to now, it was assumed that CRISPR-Cas13 systems are triggered when two criteria are met: a match between a target RNA and the system's guide RNA and the presence of an additional flanking sequence,” Elena Vialetto, PhD student at the HIRI and first author of the study, explains. The invading virus cannot replicate in this environment, restricting viral spread to other bacteria. In systems that rely on Cas13 nucleases, the immune response manifests through widespread ribonucleic acid (RNA) degradation, which causes the cell to go dormant. Beisel heads the RNA Synthetic Biology Department at the Helmholtz Institute for RNA-based Infection Research (HIRI) in Würzburg, a site of the Helmholtz Centre for Infection Research (HZI) in Braunschweig in cooperation with the Julius-Maximilians-Universität (JMU) Würzburg, and is the corresponding author of the study.ĬRISPR-Cas defense systems, which are present in bacteria and protect them from viral attacks, regularly have to decide whether or not to trigger an immune response. “In order to treat infectious and autoimmune diseases, it is critical to understand how immune systems make these decisions,“ says Chase Beisel.
Failure to recognize an attacker exposes the host to a potentially fatal infection, while erroneous recognition of the host itself can trigger an autoimmune response. The scientists published their findings in the journal “Cell Host & Microbe”.ĭistinguishing self from non-self poses a major challenge for immune systems. This discovery opens new opportunities for the use of CRISPR-Cas13 in the treatment of hereditary and infectious diseases. But what happens if the host genome shares the same sequences? A research team of the Helmholtz Institute in Würzburg in cooperation with the North Carolina State University (USA) has now discovered a control mechanism exhibited by CRISPR-Cas systems that use Cas13 nucleases: these systems only trigger an extensive immune response if the concentration of the target RNA exceeds a certain threshold. Prokaryotic CRISPR-Cas systems recognize invaders based on genetic sequence. They must recognize and clear foreign invaders without eliciting autoimmunity. Würzburg/Braunschweig, J– Friend or foe? Immune systems constantly face this question.
0 kommentar(er)
